Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPAR-PKD trial of pemafibrate in autosomal dominant polycystic kidney disease
jRCTs031250001Recruiting
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of pemafibrate in autosomal dominant polycystic kidney disease (ADPKD) (2 arms). Primary endpoint: Primary: percentage of patients with at least a 15% decline in eGFR at 36 months. Started Apr 2025; status: recruiting.
02
Drugs
pemafibrate
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on jRCTs031250001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250001.